- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01788670
Relevance of the Ethanol Dose in the Generation of Endogenous Hydroxytyrosol
February 7, 2013 updated by: Parc de Salut Mar
Hydroxytyrosol as an Endogenous and Natural Antioxidant: Modulation by Alcohol Intake. Substudy 1. Evaluating the Relevance of the Ethanol Dose in the Generation of Endogenous Hydroxytyrosol (DOPET).
Health benefits for humans derived from low dose intake of ethanol could partially be explained by its interaction with dopamine (DA) oxidative metabolism.
Ethanol is expected to induce an increase in the formation of a DA minor metabolite: DOPET (hydroxytyrosol).
Hydroxytyrosol is one of the most potent antioxidants present in Mediterranean Diet.
The study is aimed at establishing the contribution of ethanol on hydroxytyrosol formation.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Barcelona, Spain, 08003
- Parc de Salut Mar
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Clinical history and physical examination demonstrating no organic or psychiatric disorders.
- The ECG and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically.
- The body mass index (BMI=weigh/height2) will range from 19 to 27 kg/m2, and the weight from 50 to 110 kg.
- Understanding and accepting the study procedures and signing the informed consent.
Exclusion Criteria:
- Not meeting the inclusion criteria.
- History or clinical evidence of alcoholism, drug abuse, or regular use of psychoactive drugs.
- Having suffered any organic disease or major surgery in the three months prior to the study start.
- History of psychiatric disorders.
- Smokers of more than 20 cigarettes per day.
- Taking more than 30 g of alcohol a day
- Regular use of any drug in the month prior to the study sessions.The treatment with single or limited doses of symptomatic medicinal products in the week prior to the study sessions will not be a reason for exclusion if it is calculated that it has been cleared completely the day of the experimental session.
- Blood donation 8 weeks before or participation in other clinical trials with drugs in the previous 12 weeks.
- Subjects with intolerance or adverse reactions to ethanol
- History or clinical evidence of gastrointestinal, liver, renal or other disorders which may lead to suspecting a disorder in drug absorption, distribution, metabolism or excretion, or that suggest gastrointestinal irritation due to drugs.
- Subjects unable to understand the nature, consequences of the study and the procedures requested to be followed.
- Subjects with positive serology to Hepatitis B, C or HIV.
To be eligible, the subjects must agree to follow a diet free from ethanol and olive oil in the 72 hours prior to the start of each session and until the end of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Water
Lemon-flavoured water (150 ml)
|
|
Active Comparator: Ethanol high dose
The high dose corresponds to 30 g of ethanol in pilot cohort 1, to 12 g of ethanol in pilot cohort 2 and to 42 g of ethanol in pilot cohort 3.
For the definitive study the high dose corresponds to 30 g of ethanol.
Ethanol was administered as a single dose of pure ethanol diluted in lemon-flavoured water (150 ml each beverage).
|
|
Active Comparator: Ethanol low dose
The low dose corresponds to 18 g of ethanol in pilot cohort 1, to 6 g of ethanol in pilot cohort 2 and to 24 g of ethanol in pilot cohort 3.
For the definitive study the low dose corresponds to 18 g of ethanol.
Ethanol was administered as a single dose of pure ethanol diluted in lemon-flavoured water (150 ml each beverage).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hydroxytyrosol biological fluids concentrations
Time Frame: 0-24h after administration
|
Hydroxytyrosol concentrations in plasma and urine
|
0-24h after administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjective drunkenness
Time Frame: 0-6h after administration
|
Ethanol subjective effects measured using a visual analog scale
|
0-6h after administration
|
Vital signs
Time Frame: 0-6h after administration
|
Blood pressure, oral temperature and heart rate
|
0-6h after administration
|
Ethanol concentration
Time Frame: 0-6h after administration
|
Ethanol blood concentrations
|
0-6h after administration
|
Ethanol metabolites concentrations
Time Frame: 0-24h after administration
|
Ethanol metabolites recovery in urine
|
0-24h after administration
|
Dopamine metabolites concentrations
Time Frame: 0-24h after administration
|
Dopamine metabolites recovery in urine
|
0-24h after administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Magí Farré, MD, PhD, Parc de Salut Mar
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2009
Primary Completion (Actual)
June 1, 2010
Study Completion (Actual)
June 1, 2010
Study Registration Dates
First Submitted
February 5, 2013
First Submitted That Met QC Criteria
February 7, 2013
First Posted (Estimate)
February 11, 2013
Study Record Updates
Last Update Posted (Estimate)
February 11, 2013
Last Update Submitted That Met QC Criteria
February 7, 2013
Last Verified
February 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Hidroxitirosol/FIS/1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contribution of Ethanol on Hydroxytyrosol Formation
-
Parc de Salut MarFundacion IMIMCompletedContribution of Wine Components in Hydroxytyrosol FormationSpain
-
Fondation Ophtalmologique Adolphe de RothschildCompletedEstimate, With the Contribution of Optimized MRI, the Prevalence of Neurological and Neurovascular Manifestations on Imaging in the Event of SARS-CoV-2France
-
The Touro College and University SystemUniversity of Vienna; Osato Research Institute; University of Mauritius; Mauritius... and other collaboratorsCompletedAssess the Effect of Green Tea on Diabetes | Assess the Effect of Fermented Papaya Pretration on Diabetes | Effects of Green Tea and FPP on C-reactive Proteins | Effects of Green Tea and FPP of Lipid Profiles in Diabetes | Effect of Green Tea and FPP on Atheroma FormationAustria, Mauritius, United States
Clinical Trials on Water
-
Essentia Water, LLCHealth Onvector Inc.Completed
-
University of ManitobaCompleted
-
University Hospital, MontpellierCompletedHealthy | Heat ExposureFrance
-
Imam Abdulrahman Bin Faisal UniversityThe Saline Water Conversion Corporation Research Institute at Al-Jubail,...CompletedDiabetes Mellitus | Glucose, High Blood | PatientsSaudi Arabia
-
University of FloridaWithdrawnWeight Loss | Appetitive Behavior | Energy Intake | Water
-
Singapore General HospitalUnknown
-
University of Novi Sad, Faculty of Sport and Physical...Dom Zdravlja NisCompleted
-
University of North Carolina, Chapel HillCompleted
-
Institute of Progressive MedicineActive, not recruiting
-
Simon Fraser UniversityRecruitingSyncope | Orthostatic Hypotension | Vasovagal SyncopeCanada